Did you know?

Stock Price Forecast. According to 7 stock analysts, the average 12-month stock price forecast for ABCL stock stock is $23.29, which predicts an increase of 436.64%. The lowest target is $12 and the highest is $32. On average, analysts rate ABCL stock stock as a strong buy.The average twelve-month price prediction for AbCellera Biologics is $21.88 with a high price target of $34.00 and a low price target of $12.00. Learn more on ABCL's analyst rating history. Do Wall Street analysts like AbCellera Biologics more than its competitors? High Growth Earnings: ABCL is forecast to remain unprofitable over the next 3 years. Revenue vs Market: ABCL's revenue (23.9% per year) is forecast to grow faster than the US market (8% per year). High Growth Revenue: ABCL's revenue (23.9% per year) is forecast to grow faster than 20% per year.13 sept 2023 ... ABCL stock has a median price target of 28.00, with a high estimate of 34.00 and a low estimate of 12.00, indicating potential for substantial ...Track AbCellera Biologics Inc (ABCL) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investors52-Week Range $3.87 - $14.97. Previous Close $4.4. Volume 1.91M. Average Volume (3M) 1.64M. Market Cap. $1.28B. Enterprise Value $1.28B. Total Cash (Recent Filing) $795.69K. Total Debt (Recent Filing) $84.03K.Jan 5, 2023 · A $14.3 billion market cap divided by 330 million shares outstanding equals a valuation of $43.33 per share. Discounting a year 2030, $43.33 valuation, using a 10% discount rate gives us a present ... After dumping hundreds of millimetres of rain across New South Wales and Queensland, severe storms have moved south, where they are forecast to bring up to …AbCellera Biologics Inc (ABCL). 4.34 -0.26 (-5.65%) USD ... Price to book value is a valuation ratio that is measured by stock price / book value per share.Dec 1, 2023 · https://www.abcellera.com. AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. ABCL stock recorded 16/30 (53%) green days with 5.07% price volatility over the last 30 days. Based on our AbCellera Biologics stock forecast, it's now a bad time to buy ABCL stock because it's trading 6.53% above our forecast. Disclaimer: This is not investment advice. The information provided is for general information purposes only.ABCL: AbCellera Biologics - Price and Consensus Chart. Get the latest Price and Consensus Chart for AbCellera Biologics from Zacks Investment ResearchABCL - Cup & Handle Breakout Trade Abcellera Biologics is a biotech stock setting up in a textbook cup with handle pattern. The stock has growing institutional sponsorship as shown in the chart from MarketSmith on the chart. It also has a relative strength ranking of 97/100. Shares formed a cup with a 37% depth and have since driftAbcellera ...Find real-time AB - AllianceBernstein Holding LP stock quotes, company profile, news and forecasts from CNN Business. Get in Touch. Micron Technology Inc., the largest US maker of computer memory semiconductors, suffered its worst stock decline in two months after warning …AbCellera Biologics Inc. (ABCL) came out with a quarterComplete AbCellera Biologics Inc. stock information by Barron Aditya Birla Capital Ltd. share price target. View 8 reports from 3 analysts offering long term price targets for Aditya Birla Capital Ltd.. Aditya Birla Capital Ltd. has an average target of 205.67. The consensus estimate represents an upside of 21.05% from the last price of 169.90. Reco - This broker has downgraded this stock from it's ...After dumping hundreds of millimetres of rain across New South Wales and Queensland, severe storms have moved south, where they are forecast to bring up to … View the ABCL premarket stock price ahead Jul 19, 2023 · Over the past year, ABCL has underperformed the S&P 500, with a price decline of 28.37% against the S&P 500's growth of 17.07%. Data by YCharts ABCL's market cap stands at $2.07B, with total debt ... Dec 1, 2023 · https://www.abcellera.com. AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company had discovery programs that are either completed, in progress, or under contract with partners. Aditya Birla Cap. share price was Rs 169

Mar 12, 2023 · Quite a few analysts cover the stock, so you could look into forecast growth quite easily. Insider Ownership Of AbCellera Biologics The definition of company insiders can be subjective and does ... Mumbai Stock Market & Finance report, prediction for the future: You'll find the Alembic Pharmaceuticals share forecasts, stock quote and buy / sell signals below. According to present data Alembic Pharmaceuticals's Alembic Pharmaceuticals Ltd shares and potentially its market environment have been in a bullish cycle in the last 12 months (if …Get in Touch. Micron Technology Inc., the largest US maker of computer memory semiconductors, suffered its worst stock decline in two months after warning …AbCellera Biologics Stock Forecast. Is AbCellera Biologics Stock Undervalued? The current AbCellera Biologics [ ABCL] share price is $4.47. The Score for ABCL is 41, which is 18% below its historic median score of 50, and infers higher risk than normal. ABCL is currently trading in the 40-50% percentile range relative to its historical Stock ...ABCL Stock Forecast - Is ABCL a buy or sell? Find out now with a free analysis on AbCellera Biologics. Should I buy or sell ABCL? ABCL Stock Analysis - [Full Report] ABCL Chart by TradingView. Antibodies Stocks Antibody Stocks Biologics Stocks Database Stocks Drug Stocks Immune Stocks Natural Stocks

ABCL - Cup & Handle Breakout Trade Abcellera Biologics is a biotech stock setting up in a textbook cup with handle pattern. The stock has growing institutional sponsorship as shown in the chart from MarketSmith on the chart. It also has a relative strength ranking of 97/100. Shares formed a cup with a 37% depth and have since driftAbcellera ...According to our research, ABCL stock is a bad long-term investment. ABCL share price has been in a bear cycle for the past year. AbCellera Biologics Inc. ……

Reader Q&A - also see RECOMMENDED ARTICLES & FAQs. Created with Sketch. Market Activity. Funds + . Possible cause: AbCellera Biologics (NASDAQ:ABCL) First Quarter 2023 ResultsKey Financial Results. Revenu.